A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-264 in Subjects With Type 1 Diabetes Mellitus

Trial ID: NCT05791201

Interventional - Phase 1/2 - Active, not recruiting

The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).

Conditions

• Type 1 Diabetes

Interventions

• VX-264

Eligibility

Inclusion criteria

• Clinical history of T1D with greater than or equal to (\>=) 5 years duration Participant is on a stable diabetic treatment Consistent use of continuous glucose monitoring (CGM) for at least 4 weeks before Screening and willingness to use CGM for the duration of the study
• Key

Exclusion criteria

• Prior islet cell transplant, organ transplant, or cell therapy

Sponsor

Vertex Pharmaceuticals Incorporated

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows